חוב כולל להון Myriad Genetics Corp (MYGN)

Myriad Genetics, Inc. (MYGN) leads the molecular analysis and hereditary cancer screening sector, pursuing profitability through insurance expansion and automation. The current total debt-to-equity ratio demonstrates financial stability, with the metric standing at 0.72. Business revenues are based on high-tech tests in reproductive medicine, while R&D and production capacities operate with maximum efficiency and precision.

The localization of Myriad Genetics, Inc. (MYGN) business in the US and the humanitarian status of its tests minimize external risks, which is reflected in the current leverage ratio (total debt to equity). This metric determines financial stability by comparing total liabilities to net assets. The calculation reveals the proportion of borrowed funds within the company's financing structure. A decrease in this ratio confirms the business's autonomy. A rational balance of loans ensures expansion without the threat of bankruptcy.